one of the earliest globally operating professional biomedical venture capital institutions in China
Sangel Capital as one of the earliest globally operating professional biomedical venture capital institutions was established in China in 2010, focusing on life science and technology, and having leading professional advantages and rich project resources in the biomedical investment industry. Sangel Capital has offices in Shenzhen, Beijing, Suzhou, and Chicago. We bring together a group of investment and advisory teams composed of industry experts, scientists, and investors in the field of life technology to manage and operate a series of RMB and USD funds.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Oct 23, 2020
Sirnaomics
|
Series D | $105M | Biopharma | — |
Oct 19, 2020
3D Medicines
|
Private Equity(PE) | ¥1.50B | Biopharma | — |